With a Brexit deal still out of sight, there have been intensified warnings in the UK about potential disruptions to medicine supplies that could follow a no-deal scenario.
Medicare could soon cover CAR-T therapies under new proposals from the US’ Centers for Medicare & Medicaid Services (CMS), which aim to also gather real-world evidence to eventually inf
NICE has approved Novartis’ CAR-T therapy Kymriah (tisagenlecleucel) for diffuse large B-cell lymphoma (DLBCL) in adults who did not respond to two or more previous treatments.
Kisaco Research’s CAR-T Congress EU could not have come at a better time – the day after it finished NICE announced it had granted funding for a new use for Novartis’ cancer cell therapy Ky
Managing patients’ expectations of CAR-T therapies is proving to be a huge challenge from when selection decisions are made, through the treatment process and when they are recovering at ho
Experience with the approved CAR-T drugs from Novartis and Gilead has shown that being able to manufacture enough products fast enough is a major issue when it comes to marketing these cutt